HI
VIRX

Harbour Investments’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

Harbour Investments’s Portfolio VIRX Stock Details VIRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-42
Closed – – 4053
2021
Q2 		$0 Hold
42
– – ﹤0.01% 4019
2021
Q1 		$0 Buy
+42
New +$438 ﹤0.01% 3752

Other funds holding VIRX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $260M AUM 30.38% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Harbour Investments's VIRX Position: Q3 2021 in Review

Harbour Investments sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q3 2021, closing a stake of 42 shares.

Harbour Investments first reported a position in VIRX in Q1 2021 and held it in 2 quarters. The position peaked at $0 in Q2 2021. 68 funds tracked by Wall St. Rank hold VIRX as of Q3 2021.

  • Harbour Investments reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q3 2021 after selling out during the quarter.
  • Harbour Investments sold 42 Viracta Therapeutics, Inc. Common Stock shares in Q3 2021.
  • Harbour Investments first reported a position in Viracta Therapeutics, Inc. Common Stock in Q1 2021 and held it in 2 quarters.
  • Harbour Investments's Viracta Therapeutics, Inc. Common Stock position peaked at $0 in Q2 2021.
  • 68 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q3 2021.

Based on Harbour Investments's 13F filing for Q3 2021, filed 15 Nov 2021.